RedHill Biopharma Ltd. Stock

Equities

RDHL

US7574682024

Pharmaceuticals

Real-time Estimate Cboe BZX 10:57:20 2024-04-16 am EDT 5-day change 1st Jan Change
0.37 USD -8.46% Intraday chart for RedHill Biopharma Ltd. -26.10% -74.79%
Sales 2022 61.8M Sales 2023 6.53M Capitalization 28.72M
Net income 2022 -71M Net income 2023 23M EV / Sales 2022 1.87 x
Net Debt 2022 103M Net cash position 2023 4.4M EV / Sales 2023 3.73 x
P/E ratio 2022
-0.12 x
P/E ratio 2023
0.37 x
Employees 113
Yield 2022 *
-
Yield 2023
-
Free-Float 99%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.03%
1 week-22.90%
Current month-23.76%
1 month-23.31%
3 months-63.93%
6 months-6.16%
Current year-72.33%
More quotes
1 week
0.40
Extreme 0.4033
0.52
1 month
0.40
Extreme 0.4033
0.56
Current year
0.40
Extreme 0.4033
1.54
1 year
0.26
Extreme 0.257
3.60
3 years
0.26
Extreme 0.257
447.20
5 years
0.26
Extreme 0.257
460.80
10 years
0.26
Extreme 0.257
888.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 09-08-02
Founder 57 09-08-02
Director of Finance/CFO - 23-01-04
Members of the board TitleAgeSince
Director/Board Member 64 15-12-31
Director/Board Member 74 10-08-25
Director/Board Member 80 10-05-02
More insiders
Date Price Change Volume
24-04-16 0.368 -8.96% 750 824
24-04-15 0.4042 -4.98% 367,811
24-04-12 0.4254 -6.32% 544,916
24-04-11 0.4541 -5.69% 540,492
24-04-10 0.4815 -3.31% 403,083

Delayed Quote Nasdaq, April 15, 2024 at 02:41 pm EDT

More quotes
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers? diarrhea. RedHill's clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
More about the company